DOCSLIB.ORG

Beyond Proteinuria: VDR Activation Reduces Renal Inflammation in Experimental Diabetic Nephropathy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Beyond Proteinuria: VDR Activation Reduces Renal Inflammation in Experimental Diabetic Nephropathy Am J Physiol Renal Physiol 302: F647–F657, 2012. First published December 14, 2011; doi:10.1152/ajprenal.00090.2011. Translational Physiology Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy Maria-Dolores Sanchez-Niño,3 Milica Bozic,1 Elizabeth Córdoba-Lanús,4 Petya Valcheva,1 Olga Gracia,1 Merce Ibarz,2 Elvira Fernandez,1 Juan F. Navarro-Gonzalez,4* Alberto Ortiz,3* and Jose Manuel Valdivielso1* 1Research Laboratory and Nephrology Department, 2Biochemistry Department, Hospital Universitari Arnau de Vilanova, IRBLLEIDA, Lleida; 3Nefrología, IIS-Fundación Jiménez Díaz, Universidad Autonoma de Madrid and Instituto Reina Sofia de Investigaciones Nefrológicas-IRSIN, Madrid; and 4Servicio de Nefrología y Unidad de Investigación, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain Submitted 8 February 2011; accepted in final form 7 December 2011 Sanchez-Niño M, Bozic M, Córdoba-Lanús E, Valcheva P, eventual decrease in GFR. Damage to highly differentiated Gracia O, Ibarz M, Fernandez E, Navarro-Gonzalez JF, Ortiz A, glomerular podocytes is thought to be an early event in DN Valdivielso JM. Beyond proteinuria: VDR activation reduces renal (35). In recent years, a direct association between inflammatory inflammation in experimental diabetic nephropathy. Am J Physiol parameters and clinical markers of glomerular as well as Renal Physiol 302: F647–F657, 2012. First published December 14, tubulointerstitial damage has been demonstrated, suggesting 2011; doi:10.1152/ajprenal.00090.2011.—Local inflammation is thought to contribute to the progression of diabetic nephropathy. The vitamin D that inflammation may be a pathogenic factor for the develop- ment and progression of DN (22). Hyperglycemia, angiotensin receptor (VDR) activator paricalcitol has an antiproteinuric effect in ␤ human diabetic nephropathy at high doses. We have explored poten- II, transforming growth factor (TGF)- 1, and proteinuria itself tial anti-inflammatory effects of VDR activator doses that do not all play roles in stimulating renal inflammation and/or fibrosis modulate proteinuria in an experimental model of diabetic nephrop- and contribute to progression of DN. athy to gain insights into potential benefits of VDR activators in those Multiple factors have been implicated in the progression of patients whose proteinuria is not decreased by this therapy. The effect DN, but inflammatory cytokines may be critical in the devel- of calcitriol and paricalcitol on renal function, albuminuria, and renal opment of diabetic complications and nephropathy. Inflamma- inflammation was explored in a rat experimental model of diabetes tory markers such as IL-6, IL-18, monocyte chemoattractant induced by streptozotocin. Modulation of the expression of mediators protein-1 (MCP-1), and TNF-␣ are increased in the serum and of inflammation by these drugs was explored in cultured podocytes. urine of patients with diabetes and DN (22). Furthermore, At the doses used, neither calcitriol nor paricalcitol significantly urinary TNF-␣ is directly related to UAE, and strategies modified renal function or reduced albuminuria in experimental dia- ␣ betes. However, both drugs reduced the total kidney mRNA expres- modulating TNF- activity are associated with antialbuminuric sion of IL-6, monocyte chemoattractant protein (MCP)-1, and IL-18. effects. This increase in inflammatory parameters occurs early Immunohistochemistry showed that calcitriol and paricalcitol reduced in the disease, correlates with the degree of albuminuria, and MCP-1 and IL-6 in podocytes and tubular cells as well as glomerular even precedes the increase in UAE (18, 37). Resident cells, infiltration by macrophages, glomerular cell NF-␬B activation, apo- such as mesangial, tubular epithelial, and podocytes, can pro- ptosis, and extracellular matrix deposition. In cultured podocytes, duce cytokines and can express molecules that are part of the paricalcitol and calcitriol at concentrations in the physiological and costimulatory pathway (30). Experimental animal models have clinically significant range prevented the increase in MCP-1, IL-6, recently provided evidence that inflammatory molecules, in- renin, and fibronectin mRNA expression and the secretion of MCP-1 cluding TNF-␣ and MCP-1, may have a causative role in the to the culture media induced by high glucose. In conclusion, in development of DN (22). experimental diabetic nephropathy VDR activation has local renal anti-inflammatory effects that can be observed even when proteinuria The vitamin D receptor (VDR) is a ligand-activated tran- is not decreased. This may be ascribed to decreased inflammatory scription factor which, after activation, recruits cofactor mol- responses of intrinsic renal cells, including podocytes, to high glucose. ecules and binds to specific DNA binding sites to modify the expression of target genes (34). There is evidence that VDR is glomerular disease; interleukins; microalbuminuria a modulator of glomerular injury. Calcitriol, the endogenous VDR ligand, decreases the glomerulosclerosis index and UAE in rats with subtotal nephrectomy (13, 31), and mice lacking DIABETIC NEPHROPATHY (DN) is the leading cause of end-stage renal disease in the Western world. Diabetes is associated with the VDR are more susceptible to hyperglycemia-induced renal an initial increase in glomerular filtration rate (GFR). DN injury (39). The combination of a VDR activator and an ACE progression is characterized by the development of microalbu- inhibitor protected mice from developing DN (41). In the minuria in patients with normal renal function, followed by a clinical setting, chronic kidney disease (CKD) patients treated progressive increase in urinary albumin excretion (UAE) and with paricalcitol (a selective VDR activator) showed a signif- icant reduction of proteinuria (measured by a semiquantitative dipstick method) after 23 wk of therapy, independently of * J. F. Navarro-Gonzalez, A. Ortiz, and J. M. Valdivielso share senior GFR, blood pressure, or ACE inhibition (1). However, in authorship. clinical trials the proteinuria response to VDR activators has Address for reprint requests and other correspondence: J. M. Valdivielso, Laboratorio de Investigación IRBLLEIDA, Hospital Universitari Arnau de not been uniform, raising the question of whether patients Vilanova, Rovira Roure 80, 25198 Lleida, Spain (e-mail: Valdivielso without reduced UAE might still be benefiting from VDR @medicina.udl.es). activator therapy. Thus, in Fishbane’s trial which included 50% http://www.ajprenal.org 1931-857X/12 Copyright © 2012 the American Physiological Society F647 Translational Physiology F648 VDR ACTIVATION IN DIABETIC NEPHROPATHY Table 1. Weight and biochemical parameters in diabetic nephropathy animal model at the end of the 4-mo follow-up Sham Diabetes DiabetesϩCalcitriol DiabetesϩParicalcitol Weight, g 393 Ϯ 10 345 Ϯ 10* 343 Ϯ 7* 343 Ϯ 13* Serum calcium, mg/dl 10.53 Ϯ 0.1 10.3 Ϯ 0.2 10.6 Ϯ 0.3 10.5 Ϯ 0.2 Serum phosphate, mg/dl 7.4 Ϯ 0.4 7.1 Ϯ 0.5 6.3 Ϯ 0.5 6.5 Ϯ 0.6 Serum creatinine, mg/dl 0.42 Ϯ 0.01 0.43 Ϯ 0.02 0.45 Ϯ 0.04 0.44 Ϯ 0.02 Serum glucose, mg/dl 91.4 Ϯ 2.08 490 Ϯ 5* 472 Ϯ 10* 505 Ϯ 9* Urine volume, ml/day 9.7 Ϯ 1 152 Ϯ 14* 148 Ϯ 19* 132 Ϯ 15* Urinary albumin/creatinine ratio, mg/mg 0.073 Ϯ 0.019 8.3 Ϯ 1.7* 6.7 Ϯ 1.6* 7.1 Ϯ 1.2* Creatinine clearance, ml/min 2.0 Ϯ 0.14 2.0 Ϯ 0.2 1.9 Ϯ 0.1 1.8 Ϯ 0.1 Values are means Ϯ SE. *P Ͻ 0.05 vs. Sham. diabetic subjects, paricalcitol decreased UAE Ͼ10% in only However, despite podocytes being key cells in proteinuria and 58% of patients (vs. 30% in the placebo group) (11). In the DN, potential direct VDR modulation of high glucose-induced VITAL trial of DN patients, differences in the primary out- inflammation in cultured podocytes had not being studied. come (% change in urinary albumin/creatinine ratio in the Thus the aim of our study was to investigate the regulation combined paricalcitol group vs. placebo) just fell short of of renal inflammatory parameters in experimental DN by statistical significance (8). However, even in patients without subantiproteinuric doses of VDR activators and the modulation reduced proteinuria, VDR activators might have beneficial by VDR activators of the inflammatory response elicited in effects. In this regard, another potential beneficial effect of cultured murine podocytes by high glucose. VDR activation is an anti-inflammatory action. In animal models of primary glomerular disease, VDR activators reduces METHODS glomerular infiltration of inflammatory cells (23). Consistently, higher serum vitamin D levels in CKD patients are associated Animal study. Thirty male Sprague-Dawley rats were rendered with decreased systemic inflammation (33). However, no ex- diabetic by intravenous administration of streptozotocin (65 mg/kg) perimental diabetes animal study had previously addressed (7). Experimental methods used with laboratory animals comply with Law 5/1995 of June 21 by “Generalitat de Catalunya” of protection of whether VDR activators may have beneficial effects on renal animals used for experimentation and other scientific finalities and the inflammation when proteinuria is not significantly reduced. In Royal Decree 1201/2005 of October 10 on the protection of animals tubular and mesangial cells, VDR activation inhibits NF-␬B, a used for experimentation and other scientific finalities. Moreover, the key transcription factor in inflammation that regulates cyto- present protocol was approved by the Ethic Animal Experimentation kine, chemokine, and adhesion molecule gene expression (4). Committee of the University of Lleida. Fig. 1. Vitamin D receptor (VDR) activation with paricalcitol or calcitriol downregulates total kidney expression of inflammatory medi- ator mRNA in experimental diabetic nephrop- athy (DN), quantified by qRT-PCR. Values are means Ϯ SE. MCP-1, monocyte chemoattrac- tant protein-1. *P Ͻ 0.05 vs. control. #P Ͻ 0.01 vs. diabetic vehicle. ϩP Ͻ 0.05 vs. dia- betic vehicle. AJP-Renal Physiol • doi:10.1152/ajprenal.00090.2011 • www.ajprenal.org Translational Physiology VDR ACTIVATION IN DIABETIC NEPHROPATHY F649 After 48 h, the presence of hyperglycemia was confirmed and nondiabetic controls.
Load more

Recommended publications
  • Isolation and Characterisation of Lymphatic Endothelial Cells From
    www.nature.com/scientificreports OPEN Isolation and characterisation of lymphatic endothelial cells from lung tissues afected by lymphangioleiomyomatosis Koichi Nishino1,2*, Yasuhiro Yoshimatsu3,4, Tomoki Muramatsu5, Yasuhito Sekimoto1,2, Keiko Mitani1,2, Etsuko Kobayashi1,2, Shouichi Okamoto1,2, Hiroki Ebana1,2,6,7, Yoshinori Okada8, Masatoshi Kurihara2,6, Kenji Suzuki9, Johji Inazawa5, Kazuhisa Takahashi1, Tetsuro Watabe3 & Kuniaki Seyama1,2 Lymphangioleiomyomatosis (LAM) is a rare pulmonary disease characterised by the proliferation of smooth muscle-like cells (LAM cells), and an abundance of lymphatic vessels in LAM lesions. Studies reported that vascular endothelial growth factor-D (VEGF-D) secreted by LAM cells contributes to LAM-associated lymphangiogenesis, however, the precise mechanisms of lymphangiogenesis and characteristics of lymphatic endothelial cells (LECs) in LAM lesions have not yet been elucidated. In this study, human primary-cultured LECs were obtained both from LAM-afected lung tissues (LAM-LECs) and normal lung tissues (control LECs) using fuorescence-activated cell sorting (FACS). We found that LAM-LECs had signifcantly higher ability of proliferation and migration compared to control LECs. VEGF-D signifcantly promoted migration of LECs but not proliferation of LECs in vitro. cDNA microarray and FACS analysis revealed the expression of vascular endothelial growth factor receptor (VEGFR)-3 and integrin α9 were elevated in LAM-LECs. Inhibition of VEGFR-3 suppressed proliferation and migration of LECs, and blockade of integrin α9 reduced VEGF-D-induced migration of LECs. Our data uncovered the distinct features of LAM-associated LECs, increased proliferation and migration, which may be due to higher expression of VEGFR-3 and integrin α9. Furthermore, we also found VEGF-D/VEGFR-3 and VEGF-D/ integrin α9 signaling play an important role in LAM-associated lymphangiogenesis.
    [Show full text]
  • The First Genome-Wide View of Vitamin D Receptor Locations and Their Mechanistic Implications
    ANTICANCER RESEARCH 32: 271-282 (2012) Review The First Genome-wide View of Vitamin D Receptor Locations and Their Mechanistic Implications CARSTEN CARLBERG1, SABINE SEUTER2 and SAMI HEIKKINEN1 1Department of Biosciences, University of Eastern Finland, Kuopio, Finland; 2Life Sciences Research Unit, University of Luxembourg, Luxembourg, Luxembourg Abstract. The transcription factor vitamin D receptor Physiological Impact of Vitamin D (VDR) is the nuclear sensor for the biologically most active in the Immune System metabolite of vitamin D, 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3). The physiological actions of the VDR and Vitamin D is a micronutrient which under ultraviolet (UV) its ligand are not only the well-known regulation of calcium radiation can also be produced in the skin (1). The most and phosphorus uptake and transport controlling bone abundant form of vitamin D is its liver hydroxylation product formation, but also their significant involvement in the 25-hydroxyvitamin D3 (25(OH)D3), serum concentrations of control of immune functions and of cellular growth and which indicate the vitamin D status of the human individual differentiation. For a general understanding of the (2). The biologically most active vitamin D metabolite is mechanisms of 1α,25(OH)2D3 signaling, it is essential to obtained from further hydroxylation of 25(OH)D3 in the monitor the genome-wide location of VDR in relation to kidney to 1α,25(OH)2D3 (3). Interestingly, the hydroxylation primary 1α,25(OH)2D3 target genes. Within the last months, of vitamin D can also take place in other tissues and a few of two chromatin immunoprecipitation sequencing (ChIP-Seq) them, such as keratinocytes and macrophages, have the studies using cells of the hematopoietic system, capacity for the full conversion of vitamin D to lymphoblastoids and monocytes, were published.
    [Show full text]
  • LSD1 Dual Function in Mediating Epigenetic Corruption of the Vitamin
    Battaglia et al. Clinical Epigenetics (2017) 9:82 DOI 10.1186/s13148-017-0382-y RESEARCH Open Access LSD1 dual function in mediating epigenetic corruption of the vitamin D signaling in prostate cancer Sebastiano Battaglia1*, Ellen Karasik2, Bryan Gillard2, Jennifer Williams2, Trisha Winchester3, Michael T. Moser2, Dominic J Smiraglia3 and Barbara A. Foster2* Abstract Background: Lysine-specific demethylase 1A (LSD1) is a key regulator of the androgen (AR) and estrogen receptors (ER), and LSD1 levels correlate with tumor aggressiveness. Here, we demonstrate that LSD1 regulates vitamin D receptor (VDR) activity and is a mediator of 1,25(OH)2-D3 (vitamin D) action in prostate cancer (PCa). Methods: Athymic nude mice were xenografted with CWR22 cells and monitored weekly after testosterone pellet removal. Expression of LSD1 and VDR (IHC) were correlated with tumor growth using log-rank test. TRAMP tumors and prostates from wild-type (WT) mice were used to evaluate VDR and LSD1 expression via IHC and western blotting. The presence of VDR and LSD1 in the same transcriptional complex was evaluated via immunoprecipitation (IP) using nuclear cell lysate. The effect of LSD1 and 1,25(OH)2-D3 on cell viability was evaluated in C4-2 and BC1A cells via trypanblueexclusion.TheroleofLSD1inVDR-mediatedgenetranscriptionwasevaluatedforCdkn1a, E2f1, Cyp24a1,andS100g via qRT-PCR-TaqMan and via chromatin immunoprecipitation assay. Methylation of Cdkn1a TSS was measured via bisulfite sequencing, and methylation of a panel of cancer-related genes was quantified using methyl arrays. The Cancer Genome Atlas data were retrieved to identify genes whose status correlates with LSD1 and DNA methyltransferase 1 (DNMT1).
    [Show full text]
  • 1Α,25‑Dihydroxyvitamin D3 Restrains Stem Cell‑Like Properties of Ovarian Cancer Cells by Enhancing Vitamin D Receptor and Suppressing CD44
    ONCOLOGY REPORTS 41: 3393-3403, 2019 1α,25‑Dihydroxyvitamin D3 restrains stem cell‑like properties of ovarian cancer cells by enhancing vitamin D receptor and suppressing CD44 MINTAO JI1*, LIZHI LIU2*, YONGFENG HOU3 and BINGYAN LI1 1Department of Nutrition and Food Hygiene, Soochow University of Public Health, Suzhou, Jiangsu 215123; 2State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‑Sen University Cancer Center, Guangzhou, Guangdong 510060; 3State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, P.R. China Received May 10, 2018; Accepted February 27, 2019 DOI: 10.3892/or.2019.7116 Abstract. Scientific evidence linking vitamin D with various the expression of CD44. These findings provide a novel insight cancer types is growing, but the effects of vitamin D on ovarian into the functions of vitamin D in diminishing the stemness of cancer stem cell‑like cells (CSCs) are largely unknown. The cancer CSCs. present study aimed to examine whether vitamin D was able to restrain the stemness of ovarian cancer. A side popula- Introduction tion (SP) from malignant ovarian surface epithelial cells was identified as CSCs, in vitro and in vivo. Furthermore, Ovarian cancer is the fourth most frequent gynecologic malig- 1α,25‑dihydroxyvitamin D3 [1α,25(OH)2D3] treatment nancy and the leading cause of tumor‑associated mortality inhibited the self‑renewal capacity of SP cells by decreasing in the USA (1). Epithelial ovarian cancer, which accounts the sphere formation rate and by suppressing the mRNA for ~90% of ovarian cancers, is generally diagnosed at an expression levels of cluster of differentiation CD44, NANOG, advanced stage (2).
    [Show full text]
  • In Vitro Targeting of Transcription Factors to Control the Cytokine Release Syndrome in 2 COVID-19 3
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424728; this version posted December 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 In vitro Targeting of Transcription Factors to Control the Cytokine Release Syndrome in 2 COVID-19 3 4 Clarissa S. Santoso1, Zhaorong Li2, Jaice T. Rottenberg1, Xing Liu1, Vivian X. Shen1, Juan I. 5 Fuxman Bass1,2 6 7 1Department of Biology, Boston University, Boston, MA 02215, USA; 2Bioinformatics Program, 8 Boston University, Boston, MA 02215, USA 9 10 Corresponding author: 11 Juan I. Fuxman Bass 12 Boston University 13 5 Cummington Mall 14 Boston, MA 02215 15 Email: [email protected] 16 Phone: 617-353-2448 17 18 Classification: Biological Sciences 19 20 Keywords: COVID-19, cytokine release syndrome, cytokine storm, drug repurposing, 21 transcriptional regulators 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424728; this version posted December 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 22 Abstract 23 Treatment of the cytokine release syndrome (CRS) has become an important part of rescuing 24 hospitalized COVID-19 patients. Here, we systematically explored the transcriptional regulators 25 of inflammatory cytokines involved in the COVID-19 CRS to identify candidate transcription 26 factors (TFs) for therapeutic targeting using approved drugs.
    [Show full text]
  • Titanium Biomaterials with Complex Surfaces Induced Aberrant Peripheral Circadian Rhythms in Bone Marrow Mesenchymal Stromal Cells
    RESEARCH ARTICLE Titanium biomaterials with complex surfaces induced aberrant peripheral circadian rhythms in bone marrow mesenchymal stromal cells Nathaniel Hassan1,2, Kirstin McCarville1,2,3☯, Kenzo Morinaga1,3,4☯, Cristiane M. Mengatto1,5, Peter Langfelder6, Akishige Hokugo1,7, Yu Tahara8, Christopher S. Colwell8, Ichiro Nishimura1,2,3* a1111111111 a1111111111 1 Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, California, a1111111111 United States of America, 2 Division of Oral Biology & Medicine, UCLA School of Dentistry, Los Angeles, a1111111111 California, United States of America, 3 Division of Advanced Prosthodontics, UCLA School of Dentistry, Los a1111111111 Angeles, California, United States of America, 4 Department of Oral Rehabilitation, Section of Oral Implantology, Fukuoka Dental College, Fukuoka, Japan, 5 Department of Conservative Dentistry, School of Dentistry Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil, 6 Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America, 7 Division of Plastic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America, 8 Department of Psychiatry & Biobehavioral Science, David Geffen School of OPEN ACCESS Medicine at UCLA, Los Angeles, California, United States of America Citation: Hassan N, McCarville K, Morinaga K, ☯ These authors contributed equally to this work. Mengatto CM, Langfelder P, Hokugo A, et al. * [email protected] (2017) Titanium biomaterials with complex surfaces induced aberrant peripheral circadian rhythms in bone marrow mesenchymal stromal cells. PLoS ONE 12(8): e0183359. https://doi.org/ Abstract 10.1371/journal.pone.0183359 Circadian rhythms maintain a high level of homeostasis through internal feed-forward and Editor: Shin Yamazaki, University of Texas -backward regulation by core molecules.
    [Show full text]
  • Vitamins D3 and D2 Have Marked but Different Global Effects on Gene
    Mengozzi et al. Molecular Medicine (2020) 26:32 Molecular Medicine https://doi.org/10.1186/s10020-020-00153-7 RESEARCH ARTICLE Open Access Vitamins D3 and D2 have marked but different global effects on gene expression in a rat oligodendrocyte precursor cell line Manuela Mengozzi1,2, Andrew Hesketh2,3, Giselda Bucca2,3, Pietro Ghezzi1,2* and Colin P. Smith2,3 Abstract Background: Vitamin D deficiency increases the risk of developing multiple sclerosis (MS) but it is unclear whether vitamin D supplementation improves the clinical course of MS, and there is uncertainty about the dose and form of vitamin D (D2 or D3) to be used. The mechanisms underlying the effects of vitamin D in MS are not clear. Vitamin D3 increases the rate of differentiation of primary oligodendrocyte precursor cells (OPCs), suggesting that it might help remyelination in addition to modulating the immune response. Here we analyzed the transcriptome of differentiating rat CG4 OPCs treated with vitamin D2 or with vitamin D3 at 24 h and 72 h following onset of differentiation. Methods: Gene expression in differentiating CG4 cells in response to vitamin D2 or D3 was quantified using Agilent DNA microarrays (n = 4 replicates), and the transcriptome data were processed and analysed using the R software environment. Differential expression between the experimental conditions was determined using LIMMA, applying the Benjamini and Hochberg multiple testing correction to p-values, and significant genes were grouped into co- expression clusters by hierarchical clustering. The functional significance of gene groups was explored by pathway enrichment analysis using the clusterProfiler package. Results: Differentiation alone changed the expression of about 10% of the genes at 72 h compared to 24 h.
    [Show full text]
  • A Review of the Role Portrayed by Vitamin D in Cancer
    Cancer Therapy & Oncology International Journal ISSN: 2473-554X Review Article Canc Therapy & Oncol Int J Volume 11 Issue 2 - June 2018 Copyright © All rights are reserved by Kiran Dahiya DOI: 10.19080/CTOIJ.2018.11.555807 A Review of the Role Portrayed by Vitamin D in Cancer Rakesh Dhankhar1, Kiran Dahiya2*, Raunak Ahlawat3, Priya Dahiya4, Sunder Singh1 and Keerti Gupta2 1Department of Radiotherapy, Pt. BD Sharma PGIMS, Rohtak, Haryana, India 2Department of Biochemistry, Pt. BD Sharma PGIMS, Rohtak, Haryana, India 3Ex-student, BPSGMCW, Khanpur Kalan, Sonepat, Haryana, India 4Department of Obstetrics and Gynecology, Rajshree Medical Research Institute, Bareilly, Uttar Pradesh, India Submission: May 07, 2018; Published: June 25, 2018 *Correspondence Address: Kiran Dahiya, Professor, Department of Biochemistry, Pt. BD Sharma PGIMS, Rohtak, Haryana, India, Tel: ; Email: Abstract homeostasis in the body and taking care of the bone health, it performs a number of important functions in the body. It can be synthesized by Vitamin D, also known as calcitriol, is not only one of the fat soluble vitamins but is a versatile hormone. Besides taking part in calcium D the body in presence of sunlight as well as can be derived from few dietary sources. Recently2 it has been observed that deficiency of vitamin D is rampant in general population around the world. Deficiency of vitamin D [1,25-(OH) 3] has now been associated with a variety of clinical diseases including cancer. Though the exact mechanism involved is not clear yet, a number of theories have been put forward for the role played by vitamin D in protection against cancer.
    [Show full text]
  • The Vitamin D Receptor: Contemporary Genomic Approaches Reveal New Basic and Translational Insights
    REVIEW SERIES: NUCLEAR RECEPTORS The Journal of Clinical Investigation Series Editor: Mitchell A. Lazar The vitamin D receptor: contemporary genomic approaches reveal new basic and translational insights J. Wesley Pike, Mark B. Meyer, Seong-Min Lee, Melda Onal, and Nancy A. Benkusky Department of Biochemistry, University of Wisconsin — Madison, Madison, Wisconsin, USA. The vitamin D receptor (VDR) is the single known regulatory mediator of hormonal 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] in higher vertebrates. It acts in the nucleus of vitamin D target cells to regulate the expression of genes whose products control diverse, cell type–specific biological functions that include mineral homeostasis. In this Review we describe progress that has been made in defining new cellular sites of action of this receptor, the mechanisms through which this mediator controls the expression of genes, the biology that ensues, and the translational impact of this receptor on human health and disease. We conclude with a brief discussion of what comes next in understanding vitamin D biology and the mechanisms that underlie its actions. Introduction involved (14, 15). With this background, we then comment briefly on In the early 1970s, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] was the current translational impact of several features of VDR action identified as both the exclusive, metabolically active form of vita- and function on human health and disease. min D and a key component of what proved to be an exquisite endo- crine system that regulates numerous biologic processes in higher The VDR vertebrates (1, 2). This pioneering discovery ended a decades-long VDR tissue distribution.
    [Show full text]
  • Vitamin D and Its Receptor Polymorphisms: New Possible Prognostic Biomarkers in Leukemias
    Oncology Reviews 2018; volume 12:366 Vitamin D and its receptor polymorphisms: New possible prognostic biomarkers in leukemias Seyed Mohammad Sadegh Pezeshki,1 Ali Amin Asnafi,1 Abbas Khosravi,1 Mohammad Shahjahani,1 Shirin Azizidoost,1 Saeid Shahrabi2 1Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 2Department of Biochemistry and Hematology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran phoma (DLBCL). There is a significant relationship between dif- Abstract ferent polymorphisms of VDR (including Taq I and Fok I) with Several factors such as chromosomal translocations, gene several leukemia types such as ALL and AML, which may have mutations, and polymorphisms are involved in the pathogenesis of prognostic value. leukemia/lymphoma. Recently, the role of vitamin D (VD) and vitamin D receptor (VDR) polymorphisms in hematologic malig- nancies has been considered. In this review, we examine the pos- Introduction sible role of VD levels, as well as VDR polymorphisms as prog- Vitamin D (VD) is a fat-soluble vitamin and an endocrine hor- nostic biomarkers in leukemia/lymphoma. Relevant English lan- mone that plays a role in bone formation and integrity via calcium guage literature were searched and retrieved from Google Scholar and phosphate absorption from the intestine and their transfer to search engine (1985-2017). The following keywords were used: bones. VD is also involved in proliferation and differentiation of vitamin D, vitamin D receptor, leukemia, lymphoma, and polymor- different malignancies including prostate, breast, bone and phism. Increased serum levels of VD in patients with leukemia are leukemias.
    [Show full text]
  • Policing Cancer: Vitamin D Arrests the Cell Cycle
    International Journal of Molecular Sciences Review Policing Cancer: Vitamin D Arrests the Cell Cycle Sachin Bhoora 1 and Rivak Punchoo 1,2,* 1 Department of Chemical Pathology, Faculty of Health Sciences, University of Pretoria, Pretoria 0083, Gauteng, South Africa; [email protected] 2 National Health Laboratory Service, Tshwane Academic Division, Pretoria 0083, South Africa * Correspondence: [email protected] Received: 30 October 2020; Accepted: 26 November 2020; Published: 6 December 2020 Abstract: Vitamin D is a steroid hormone crucial for bone mineral metabolism. In addition, vitamin D has pleiotropic actions in the body, including anti-cancer actions. These anti-cancer properties observed within in vitro studies frequently report the reduction of cell proliferation by interruption of the cell cycle by the direct alteration of cell cycle regulators which induce cell cycle arrest. The most recurrent reported mode of cell cycle arrest by vitamin D is at the G1/G0 phase of the cell cycle. This arrest is mediated by p21 and p27 upregulation, which results in suppression of cyclin D and E activity which leads to G1/G0 arrest. In addition, vitamin D treatments within in vitro cell lines have observed a reduced C-MYC expression and increased retinoblastoma protein levels that also result in G1/G0 arrest. In contrast, G2/M arrest is reported rarely within in vitro studies, and the mechanisms of this arrest are poorly described. Although the relationship of epigenetics on vitamin D metabolism is acknowledged, studies exploring a direct relationship to cell cycle perturbation is limited. In this review, we examine in vitro evidence of vitamin D and vitamin D metabolites directly influencing cell cycle regulators and inducing cell cycle arrest in cancer cell lines.
    [Show full text]
  • Micrornas and Immunomodulation By
    MICRORNAS AND IMMUNOMODULATION BY VITAMIN D By DANYANG LI A thesis submitted to the University of Birmingham for the degree of DOCTOR OF PHILOSOPHY Institute of Metabolism and Systems Research College of Medical and Dental Sciences University of Birmingham January 2019 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Abstract The active form of vitamin D, 1,25(OH)2D3, plays well-established roles in calcium regulation and bone formation. 1,25(OH)2D3 is also thought to exert immunoregulatory effects upon cells of the innate (dendritic cell) and adaptive (T cell) immune systems, that may impact health and disease. In recent years, the role of 1,25(OH)2D3 has been implicated in autoimmune diseases such as rheumatoid arthritis (RA). 1,25(OH)2D3 brings about genetic and epigenetic changes within immune cells, the latter which may include effects of microRNAs (miRNAs); small non-coding RNAs with an important regulatory role. To study the role of 1,25(OH)2D3 on miRNAs in RA, we utilised n=20 (RA) and n=7 (reactive arthritis, ReA) matched patient serum and synovial fluid (SF) samples to derive measurements of vitamin D metabolite concentrations by LC-MS/MS, vitamin D binding protein abundance by ELISA, and circulating miRNA expression by qPCR.
    [Show full text]